Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Capsules
Patent
1984-12-20
1987-12-29
Griffin, Ronald W.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Capsules
424462, 424468, 424473, 424490, 424497, 514965, A61K 950, A61K 958
Patent
active
047160403
ABSTRACT:
A controlled absorption methyldopa formulation for oral administration comprises a pellet having a core of methyldopa or a pharmaceutically acceptable salt thereof in association with an organic acid, and an outer membrane which permits release of methyldopa in an aqueous medium at a controlled rate which is substantially pH independent. The pellet has a dissolution rate in vitro, which when measured in a Basket Assembly according to U.S. Pharmacopoeia XX at 37.degree. C. and 75 r.p.m., is not more than 50% of the total methyldopa after one hour of measurement. Not more than 80% of the total methyldopa is released after a total of 3 hours of measurement and 100% release is achieved after a total of 7 hours.
REFERENCES:
patent: 3965255 (1976-06-01), Bloch et al.
patent: 4230687 (1980-10-01), Sair et al.
patent: 4263273 (1981-04-01), Appelgren et al.
patent: 4361546 (1982-11-01), Stricker et al.
patent: 4367217 (1983-01-01), Gruber et al.
patent: 4438091 (1984-03-01), Gruber et al.
patent: 4499066 (1985-02-01), Moro et al.
patent: 4555399 (1985-11-01), Hsiao
patent: 4592753 (1986-06-01), Panoz
patent: 4600645 (1986-07-01), Ghebre-Sellassie et al.
patent: 4609542 (1986-09-01), Panoz et al.
patent: 4610870 (1986-09-01), Jain et al.
Elan Corporation P.L.C.
Griffin Ronald W.
LandOfFree
Controlled absorption methyldopa pharmaceutical formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled absorption methyldopa pharmaceutical formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled absorption methyldopa pharmaceutical formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-462366